Elanco Animal Health Reports the US FDA’s Approval of Zenrelia (Ilunocitinib) to Treat Canine Dermatological Disorders
Shots:
- The US FDA has approved Elanco’s Zenrelia (QD, oral), a JAK inhibitor, to manage pruritus (itching) linked with allergic dermatitis and atopic dermatitis in dogs (at least 12mos.)
- The approval was supported by a head-to-head study assessing the safety & efficacy of Zenrelia vs Apoquel (oclacitinib) in dogs (n=338) with confirmed atopic dermatitis at 25 sites across 4 countries
- Study demonstrated greater and sustained itch relief with Zenrelia vs Apoquel post day 14, with 77% vs 53% of dogs achieving clinical remission of itch; both treatments had similar AE profiles. Owners and vets rated Zenrelia higher for overall response from day 28 to day 112
Ref: Elanco | Image: Elanco
Related News:- Elanco Reports the US FDA’s Review Completion of Bovaer to be Used Across the US Dairy Industry
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
